UroGen Pharma Drops To US$12.74, Yet Insiders May Have Sold Too Early

UroGen Pharma Ltd.'s (NASDAQ:URGN) value has fallen 11% in the last week, but insiders who sold US$307k worth of stock over the last year have had less success. Insiders might have been better off holding onto their shares, given that the average selling price of US$14.78 is still below the current share price.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

View our latest analysis for UroGen Pharma

UroGen Pharma Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider sale was by the Chief Medical Officer, Mark Schoenberg, for US$169k worth of shares, at about US$14.05 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$12.74. So it is hard to draw any strong conclusion from it.

UroGen Pharma insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

UroGen Pharma Insiders Are Selling The Stock

The last three months saw significant insider selling at UroGen Pharma. In total, Chief Medical Officer Mark Schoenberg sold US$169k worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap.

Insider Ownership Of UroGen Pharma

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that UroGen Pharma insiders own 6.9% of the company, worth about US$30m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Does This Data Suggest About UroGen Pharma Insiders?

An insider sold stock recently, but they haven't been buying. And even if we look at the last year, we didn't see any purchases. While insiders do own shares, they don't own a heap, and they have been selling. We're in no rush to buy! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing UroGen Pharma. Our analysis shows 3 warning signs for UroGen Pharma (1 is significant!) and we strongly recommend you look at them before investing.

But note: UroGen Pharma may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.